Investigators analyzed the relationship among low heart rate at 24hECG, premature atrial contractions, and incident atrial fibrillation in a prospective population-based cohort.
The CHA2DS2VASc score is a sensitive tool for predicting new-onset atrial fibrillation and adverse outcomes in individuals with and without atrial fibrillation.
Treatment with direct oral anticoagulants (DOAC) at discharge following acute ischemic stroke among patients with atrial fibrillation is an effective and safe treatment option, with a superior risk-benefit ratio compared with warfarin.
Children and young adults treated with amiodarone have a significant likelihood for thyroid dysfunction soon after treatment initiation.
Use of antiarrhythmic drugs is associated with a higher risk for fall-related injuries and syncope among older patients with atrial fibrillation.
The risk of sudden cardiac death was present across all strata of left ventricular ejection fraction and was related to the use of cocaine, lower use of beta-blockers, lower CD4, and nonsuppressed viral load.
A new clinical statement on the emergency management of patients with ventricular assist devices was released by a consensus written by members of the Heart Failure Society of America, the Society for Academic Emergency Medicine, and the International Society for Heart and Lung Transplantation.
An AI-enabled electrocardiograph acquired during normal sinus rhythm can identify individuals with atrial fibrillation.
Higher HbA1c levels in the year prior to ablation were linked to an increased risk for post-ablation AF recurrence in patients with diabetes.
The FDA has accepted for review the resubmitted New Drug Application (NDA) for Brinavess (vernakalant hydrochloride; Correvio Pharma) as a treatment for the rapid conversion of adult patients with recent onset atrial fibrillation.
